MedTrace Logo

Fluorescence Targeted Pelvic Lymph Node Mapping

NCT03204994 · Status: TERMINATED · Phase: PHASE1/PHASE2 · Type: INTERVENTIONAL · Enrollment: 1

Last updated 2019-08-13

No results posted yet for this study

Summary

This study aims to assess the lymphatic drainage of rectal tumours by using ICG as a fluorescent non-specific marker. As a feasibility study, it will also assess its technique and timing along with its ability to assist in removing lymph nodes when it is clinically indicated.

Conditions

  • Cancer of Rectum
  • Lymph Node Disease

Interventions

DRUG

Indocyanine Green

Fluorescence guided lymphatic mapping using indocyanine green.

Sponsors & Collaborators

  • Oxford University Hospitals NHS Trust

    lead OTHER

Principal Investigators

  • Chris Cunningham, MD · Chief Investigator

  • Thomas Barnes, MBChB · Clinical Research Fellow

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2017-08-01
Primary Completion
2018-07-01
Completion
2018-08-01

Countries

  • United Kingdom

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03204994 on ClinicalTrials.gov